Pfizer Inc
NYSE: PFE
$24.80
-$1.22 (-4.7%)
Closing Price on November 15, 2024
PFE Articles
The week ahead is going to be a busy week. There are many traditional events to watch, but by now the market participants and investors have learned that they have to pay close attention to many...
Published:
Last Updated:
Usually, shares of drug makers soar following the announcement that the Foood and Drug Administration approved a drug. Amarin Corp. (NASDAQ: AMRN) announced approval by the FDA for Vascepta to...
Published:
A new treatment for Alzheimer’s disease from Pfizer Inc. (NYSE: PFE) and partner Elan Corp. plc (NYSE: ELN) has failed a late-stage trial in patients with mild-to-moderate cases of the disease and...
Published:
Carlyle (NASDAQ: CG) may buy a unit of United Technologies (NYSE: UTX). (Reuters) More factories move to the United States as China’s manufacturing costs rise. (Reuters) The CEOs of Apple (NASDAQ:...
Published:
When Gallup asked people about the state of the economy this spring, as a recovery appeared to have taken hold, the polling company found “nearly half of Americans, 46%, still say the economy is in...
Published:
Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from Bristol-Myers...
Published:
Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but missed slightly on revenues. The drug maker reported...
Published:
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s...
Published:
Last Updated:
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
Published:
Last Updated:
Some mergers are very straight-forward, and others are just odd. Now we have an answer over whether or not Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) was going to be acquired or not. ...
Published:
Last Updated:
Some products sell well when first introduced. Many more fail miserably. Very few of them sell so well that they fundamentally impact American culture. This is 24/7 Wall St.’s list of 10 products...
Published:
Last Updated:
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the price appears to be more finite. We have heard enough names around this diabetes treatment...
Published:
Last Updated:
China’s PMI indicates a considerable slowing of its economy. (Reuters) Senior EC and ECB officials warn that the eurozone is on the brink of a calamity. (Reuters) Problems at Research In Motion...
Published:
The 10-year Treasury hit yet another record low under 1.6% today and stocks are in the tank again due to poor economic data. Europe continues to face a meltdown and the hope is for a rate cut out...
Published:
Last Updated:
A stock market that sells off eight of nine days is not a good market. Even the Facebook IPO is being viewed as a one-off item rather than a systemic item which will make the market stronger. ...
Published:
Last Updated: